San Diego

ZeaKal's $10 million financing tops recent funding news in San Diego

AI Assisted Icon
Published on July 09, 2019
ZeaKal's $10 million financing tops recent funding news in San DiegoPhoto: M. B. M./Unsplash

San Diego-based plant-science company ZeaKal has secured $10 million in a corporate round, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced on June 19 and financed by Canopy Rivers.

According to its Crunchbase profile, "ZeaKal is a plant-science company developed from the incubation pipeline of Kapyon Ventures. The company’s HME [Heat and Moisture Exchange] technology has been shown to vastly increase the yield and oil content of multiple crops—meaningfully impacting the demand for biomass across food, feed and fuels."

The 9-year-old company has raised two previous funding rounds, including a $5.3 million Series B round in 2016.

In other local funding news, e-commerce and marketplace company Mercato announced a $4 million seed funding round on July 1, led by Greycroft.

According to Crunchbase, "Mercato is a technology start-up that connects consumers to local specialty food shops. Consumers can order fresh local groceries online from the stores they love, and have them delivered to their door."

Founded in 2015, the company has raised four previous rounds, including a $1 million seed round in 2018.

Meanwhile, biotechnology and electronics company Biological Dynamics raised grant funding, announced on July 1. The round was financed by Bill & Melinda Gates Foundation.

From the company's Crunchbase profile, "Biological Dynamics Inc. is an early stage company that has developed a proprietary AC Electrokinetic technology to rapidly extract nanoparticles in high-conductance physiological solutions. Biological Dynamics was founded in 2008 by Raj Krishnan and David Charlot, bioengineering Ph.D. graduates from the University of California, San Diego (UCSD). Our vision is to enable healthcare practitioners to detect, diagnose and monitor cancer and other diseases from a simple blood draw (or other bodily fluid) and rapidly intervene, increasing patient survivability while driving down the total burden costs."

Biological Dynamics last raised $26 million in Series C funding in 2015.


This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.